NEURACAP

Research reports, page 6

Sector outlooks, company valuation reports and M&A updates on public markets.

For information only. Not an appraisal or a fairness opinion.

404 reports · page 6 of 17

Browse by sector →
Cover of Biotechnology Sector Outlook — September 2026Sector Outlook

Health Care

Biotechnology Sector Outlook — September 2026

A sector outlook on 85 biotechnology companies, showing how clinical-stage pipelines and launched biologics revenue price differently, and what buyers have paid in recent transactions. For boards and management teams benchmarking a biotech business.

Biotechnology · 23 pages · Free to read

Cover of Specialty and Branded Pharmaceuticals M&A update, 14–28 September 2026M&A Update

Health Care

Specialty and Branded Pharmaceuticals M&A update, 14–28 September 2026

A bi-weekly briefing on Specialty and Branded Pharmaceuticals covering public market moves, major disclosures and M&A activity from September 14–28, 2026, built for corporate development, IR and deal teams tracking sector-wide repricing and transaction signals.

Specialty and Branded Pharmaceuticals · 7 pages · Free to read

Cover of Generic and Non-Prescription Drugs M&A update, 14–28 September 2026M&A Update

Health Care

Generic and Non-Prescription Drugs M&A update, 14–28 September 2026

A bi-weekly update on the Generic and Non-Prescription Drugs sector for September 14–28, 2026, covering share-price moves across ten covered names, the period's approval and launch news, and the standing M&A precedent record — built for operators, acquirers and advisers tracking the space.

Generic and Non-Prescription Drugs · 7 pages · Free to read

Cover of Health Care Workforce Services M&A update, 14–28 September 2026M&A Update

Health Care

Health Care Workforce Services M&A update, 14–28 September 2026

A bi-weekly briefing on Health Care Workforce Services covering price moves, company news, legal developments and the M&A precedent record for September 14–28, 2026. Built for operators, acquirers and advisors tracking staffing, credentialing and physician practice management economics.

Health Care Workforce Services · 7 pages · Free to read

Cover of Specialty and Branded Pharmaceuticals Sector Outlook — September 2026Sector Outlook

Health Care

Specialty and Branded Pharmaceuticals Sector Outlook — September 2026

This report compares how public markets price specialty and branded pharmaceutical business models—pipelines, hybrid portfolios and diversified platforms—on EV/Revenue, profitability and precedent transactions. Written for owners, boards and management teams weighing portfolio and capital choices.

Specialty and Branded Pharmaceuticals · 23 pages · Free to read

Cover of Health Care Workforce Services Sector Outlook — September 2026Sector Outlook

Health Care

Health Care Workforce Services Sector Outlook — September 2026

A sector view of six listed health care workforce companies, comparing EV/EBITDA (CY2027E) across three business models - learning & competency platforms, hospital-based physician practice management and staffing - for investors, boards and management assessing where premium value sits.

Health Care Workforce Services · 20 pages · Free to read

Cover of Generic and Non-Prescription Drugs Sector Outlook — September 2026Sector Outlook

Health Care

Generic and Non-Prescription Drugs Sector Outlook — September 2026

A sector view of Generic and Non-Prescription Drugs, covering how public markets price complex generics, branded off-patent portfolios and consumer self-care brands, with precedent transaction benchmarks. Built for owners, boards and acquirers assessing where a business sits in this range.

Generic and Non-Prescription Drugs · 21 pages · Free to read

Cover of Pharmaceuticals M&A update, 14–28 September 2026M&A Update

Health Care

Pharmaceuticals M&A update, 14–28 September 2026

NeuraCap's bi-weekly pharmaceuticals update tracks price moves, company news and M&A activity across 19 covered names for September 14–28, 2026. Built for operators, acquirers and advisers tracking sector-relative performance, deal multiples and the news driving them.

Pharmaceuticals · 7 pages · Free to read

Cover of Health Care Data and Analytics M&A update, 14–28 September 2026M&A Update

Health Care

Health Care Data and Analytics M&A update, 14–28 September 2026

This bi-weekly update tracks share-price moves, company news and M&A activity across nine covered Health Care Data and Analytics names for September 14–28, 2026. It is built for operators, acquirers and advisors monitoring sector valuation and deal reference points.

Health Care Data and Analytics · 7 pages · Free to read

Cover of Pharmaceuticals Sector Outlook — September 2026Sector Outlook

Health Care

Pharmaceuticals Sector Outlook — September 2026

This report maps pharmaceuticals by business model, valuation and precedent transactions, showing where earnings durability supports premium pricing. Built for owners, management teams and boards assessing portfolio strategy, exclusivity risk and cost-structure resilience.

Pharmaceuticals · 22 pages · Free to read

Cover of Genetic and Screening Services M&A update, 14–28 September 2026M&A Update

Health Care

Genetic and Screening Services M&A update, 14–28 September 2026

This bi-weekly update tracks share-price moves, company announcements and M&A activity across Genetic and Screening Services for September 14–28, 2026, for operators, acquirers and advisors tracking regulatory and clinical evidence catalysts in the sector.

Genetic and Screening Services · 7 pages · Free to read

Cover of Health Care Data and Analytics Sector Outlook — September 2026Sector Outlook

Health Care

Health Care Data and Analytics Sector Outlook — September 2026

This sector outlook examines Health Care Data and Analytics through public valuations, precedent transactions and business-model comparisons, for owners, operators and boards weighing revenue quality, data rights and margin conversion.

Health Care Data and Analytics · 22 pages · Free to read

Cover of Digital Health and Telehealth M&A update, 14–28 September 2026M&A Update

Health Care

Digital Health and Telehealth M&A update, 14–28 September 2026

A bi-weekly read on Digital Health and Telehealth: what moved in the public market, what companies announced, and what changed in the transaction record, for operators, acquirers and advisors tracking the sector week to week.

Digital Health and Telehealth · 7 pages · Free to read

Cover of Genetic and Screening Services Sector Outlook — September 2026Sector Outlook

Health Care

Genetic and Screening Services Sector Outlook — September 2026

A sector outlook on Genetic and Screening Services for investors and operators, covering valuation across testing and adjacent models, growth-driven multiples, precedent transactions and strategic priorities for owners and management teams.

Genetic and Screening Services · 20 pages · Free to read

Cover of Home Health and Long-Term Care M&A update, 14–28 September 2026M&A Update

Health Care

Home Health and Long-Term Care M&A update, 14–28 September 2026

A bi-weekly briefing on Home Health and Long-Term Care public market moves, company announcements and M&A activity for September 14–28, 2026. Built for operators, acquirers and advisors tracking density-building deals, governance and legal items, and the trailing precedent set that anchors deal pricing.

Home Health and Long-Term Care · 7 pages · Free to read

Cover of Digital Health and Telehealth Sector Outlook — September 2026Sector Outlook

Health Care

Digital Health and Telehealth Sector Outlook — September 2026

A sector-wide view of how the market prices Digital Health and Telehealth companies on forward revenue, comparing platforms, care delivery and adjacent business models. Built for investors, boards and management teams weighing where growth and business-model mix show up in valuation.

Digital Health and Telehealth · 23 pages · Free to read

Cover of Home Health and Long-Term Care Sector Outlook — September 2026Sector Outlook

Health Care

Home Health and Long-Term Care Sector Outlook — September 2026

A sector-wide look at Home Health and Long-Term Care valuations, growth drivers and precedent transactions, built for owners, operators and boards assessing where earnings durability supports premium multiples as of September 2026.

Home Health and Long-Term Care · 22 pages · Free to read

Cover of Clinical Laboratory Services M&A update, 14–28 September 2026M&A Update

Health Care

Clinical Laboratory Services M&A update, 14–28 September 2026

A bi-weekly update on Clinical Laboratory Services covering public market movers, company news and M&A activity for September 14–28, 2026. Built for operators, acquirers and advisors tracking coverage, coding and reimbursement developments alongside the sector's deal record.

Clinical Laboratory Services · 7 pages · Free to read

Cover of Outpatient and Specialty Care Services M&A update, 14–28 September 2026M&A Update

Health Care

Outpatient and Specialty Care Services M&A update, 14–28 September 2026

A bi-weekly read on outpatient and specialty care services: public market moves, major company events and M&A activity across September 14–28, 2026, built for owners, acquirers and advisors tracking the sector's disclosure and valuation signals.

Outpatient and Specialty Care Services · 7 pages · Free to read

Cover of Clinical Laboratory Services Sector Outlook — September 2026Sector Outlook

Health Care

Clinical Laboratory Services Sector Outlook — September 2026

A sector outlook on Clinical Laboratory Services covering scaled lab networks, specialty diagnostics and adjacent models. It sets out how growth, business model and reimbursement durability shape EV/Revenue valuation, alongside precedent transaction benchmarks, for executives and boards assessing capital allocation

Clinical Laboratory Services · 22 pages · Free to read

Cover of Outpatient and Specialty Care Services Sector Outlook — September 2026Sector Outlook

Health Care

Outpatient and Specialty Care Services Sector Outlook — September 2026

A September 2026 sector outlook on Outpatient and Specialty Care Services, covering the public comparable universe, valuation drivers, precedent transactions and strategic implications for owners, operators and boards assessing business model and operating performance.

Outpatient and Specialty Care Services · 22 pages · Free to read

Cover of Cardiovascular Devices M&A update, 14–28 September 2026M&A Update

Health Care

Cardiovascular Devices M&A update, 14–28 September 2026

A bi-weekly update on cardiovascular devices covering public market moves, major company news and M&A activity for September 14–28, 2026, built for investors, operators and advisors tracking performance and deal activity across the sector.

Cardiovascular Devices · 7 pages · Free to read

Cover of Hospitals and Health Systems M&A update, 14–28 September 2026M&A Update

Health Care

Hospitals and Health Systems M&A update, 14–28 September 2026

This bi-weekly update tracks public market moves, company news and M&A activity across hospitals and health systems for September 14–28, 2026, built for operators, acquirers and advisors monitoring capacity, staffing and valuation trends in the sector.

Hospitals and Health Systems · 7 pages · Free to read

Cover of Hospitals and Health Systems Sector Outlook — September 2026Sector Outlook

Health Care

Hospitals and Health Systems Sector Outlook — September 2026

This report reviews the Hospitals and Health Systems sector as of September 28, 2026, comparing 8 listed operators on EV/EBITDA (CY2027E) and setting recent precedent transaction multiples alongside the public peer range.

Hospitals and Health Systems · 22 pages · Free to read

Need this for your own company?

Company valuation reports are built on the same evidence base as the research above — public or private, any sector.